California State Controller, Malia Cohen (left) presents Helio Genomics CEO Justin Chen Li (right) with the CIF 2024 Innovation Award for AI Based Medical Technology.
Helio Genomics has been honored by the California Investment Forum (CIF) for its innovations in utilizing AI-based technology in developing its HelioLiver test for early liver cancer detection.
Helio was presented with a 2024 Innovation Award for AI-Based Medical Technology as applied to its HelioLiver. HelioLiver is a multi-analyte blood test that analyzes cell-free DNA (cfDNA), methylation patterns, serum protein markers and demographic information with a simple blood draw to detect hepatocellular carcinoma, or HCC, the most common form of liver cancer.
